Genta Initiates Genasense Plus Thalidomide Trial in Myeloma
BERKELEY HEIGHTS, New Jersey-Genta Incorporated has initiated a new clinical trial with its lead anticancer drug Genasense in patients with multiple myeloma. The study will assess the safety and efficacy of Gena-sense in combination with thalidomide (Thalomid) and dexamethasone in patients who have failed standard therapy. The trial will be conducted at the University of Maryland and is sponsored by the NCI pursuant to Genta’s Cooperation Research and Development Agreement (CRADA). Genasense works by inhibiting the production of Bcl-2, a protein made by cancer cells that blocks chemotherapy-induced cell death. Genasense may enhance the effectiveness of current anticancer treatments, Genta said in a news release.
BERKELEY HEIGHTS, New JerseyGenta Incorporated has initiated a new clinical trial with its lead anticancer drug Genasense in patients with multiple myeloma. The study will assess the safety and efficacy of Gena-sense in combination with thalidomide (Thalomid) and dexamethasone in patients who have failed standard therapy. The trial will be conducted at the University of Maryland and is sponsored by the NCI pursuant to Genta’s Cooperation Research and Development Agreement (CRADA). Genasense works by inhibiting the production of Bcl-2, a protein made by cancer cells that blocks chemotherapy-induced cell death. Genasense may enhance the effectiveness of current anticancer treatments, Genta said in a news release.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
